(CHEK) Check Cap - Ratings and Ratios

Check-Cap Ltd. (NASDAQ:CHEK) is a clinical-stage medical diagnostics company specializing in the development of innovative capsule-based screening solutions. The companys flagship technology leverages ultra-low-dose X-rays to non-invasively scan the inner lining of the colon, detecting precancerous polyps and other structural abnormalities. This approach aims to improve early detection of colorectal cancer through a patient-friendly, minimally invasive method. The C-Scan system is comprised of three core components: the C-Scan Cap, a swallowed capsule that captures X-ray images; the C-Scan Track, a wearable, disposable system that adheres to the patients back via biocompatible skin patches to track capsule movement; and the C-Scan View software, which processes data, generates reports, and enables physician analysis. Headquartered in Isfiya, Israel, the company has been advancing its technology since its incorporation in 2004. Learn more.

As of the latest data, Check-Cap Ltd. is listed on the NASDAQ under the ticker CHEK, classified as a common stock within the Health Care Equipment sector. The company operates out of Israel, reflecting its roots in the regions robust medical technology ecosystem. Its market capitalization stands at $4.51 million USD, with a price-to-book ratio of 0.26, indicating a potentially undervalued stock relative to its book value. However, the return on equity (RoE) is negative at -70.86, signaling financial challenges. The stocks average 20-day trading volume is 48,550 shares, with a last price of $0.75. Key technical indicators include SMA-20 at $0.83, SMA-50 at $1.05, and SMA-200 at $1.46, while the Average True Range (ATR) is $0.12, reflecting moderate price volatility.